-
Dr Sharman's Blogs
Recent Comments
Gerald Goldstein on Ibrutinib in the News Webmaster on Ibrutinib in the News T on Ibrutinib in the News
Web-based Training & More…
gotCLL.com is currently being upgraded with new content and updated links. Among the additions is a link to a resource for those who wish to learn more about cancer and cancer research. The information and links on the Specific path are duplicated, below.
Web-based e-Training on Cancer Research
The Cancer Information Support Network (CISN) offers free certified web-based training for patients, advocates and medical professionals who want to better understand cancer research. → More…
An overview and a complete outline of the six sections of the e-training are available. The sections include:
- Cancer 101
- What We Know About Cancer
- How Cancer is Studied
- Drug Development
- New Horizons in Cancer Care
- Personalized Medicine
Each section will require one to two hours to read while each quiz will takek 45 minutes to and hour. No previous background is assumed, and each sub-section can be read individually.
New Health Care Issues Page
The current fiscal crisis in Washington is creating all sorts of problems, especially for patients requiring expensive cancer drugs and care. A new page, Health Care Issues, has been added as a place to locate related information sources and issues, especially those which are enduring or particularly noteworthy. A link to it appears on the For Patients & Caregivers drop-down menu.
Posted in News, Website News & Business
Leave a comment
Ibrutinib in the News
Recently, the big news in our CLL universe is about Ibrutinib. You may have read about it in the Forbes article, The Wild Story Behind A Promising Experimental Cancer Drug, on WebMD blog, or in a local media article , e.g., New Drug to Help Battle Cancer.
I recommend that those interested in this news about Ibrutinib read the post, History of Ibrutinib, on Dr. Sharman’s CLL & Lymphoma Blog. He concludes,
For a drug likely to cost nearly $90k per year (my guess only) – insurance will likely look quite closely at who is receiving it. While CLL patients will greet the approval – it may still take a while for them to access the medicine. That is why getting involved in research studies is so important!!!!
For more Ibrutinib insights, check out these other related posts by Dr. Sharman.
___________
April 22, 2013
Blood Cancers Update:
Breakthrough Drug Ibrutinib Continues to Impress in Chronic Lymphocytic Leukemia
x
x
Source: Cure Magazine Newsletter
__________
April 8, 2013
Infographic: A Healthcare Q&A Map
ciick this to see the complete map
CURE Today has published an informative graphic, a portion of which is appears, above. The complete graphic presents a series of questions related to CLL and the health care providers to whom they should be posed. It provides a clear and simple overview for patients, family, and friends who often may ask, “Who do I ask?”
A related article, “KnowingYour Healthcare Team,” by Maureen Salamon. CURE, Spring 2013, is available, here. [Note: The link at the bottom of the full graphic is incorrect.]
Posted in Ask the Doctor, Caregiver, CLL Patient, Occasional Musing
Tagged Caregivers, Questions
Leave a comment
